bovnews1 小时
Halozyme Therapeutics, Inc. (HALO) Stock Sees Market Value Hit $5.70 billion: What Are the ...
On Tuesday, Halozyme Therapeutics, Inc. (HALO) stock saw a modest uptick, ending the day at $44.81 which represents a slight increase of $2.24 or 5.26% from the prior close of $42.57. The stock opened ...
Halozyme: Fabless Or Not, The Stock Is Now A Steal On Evotec Deal
Halozyme's strategic acquisition of Evotec and innovative ENHANZE technology present growth opportunities. Click here for a ...
bovnews1 天
What’s Causing Halozyme Therapeutics, Inc. (HALO) Stock’s 2.10% Jump Over the Last Six ...
On Friday, Halozyme Therapeutics, Inc. (HALO) stock saw a decline, ending the day at $45.65 which represents a decrease of $-8.31 or -15.40% from the prior close of $53.96. The stock opened at $48.81 ...
腾讯网2 天
奥洛兹美医疗(HALO.US)拟以21亿美元现金收购Evotech(EVO.US)
智通财经APP获悉，据外媒报道， 奥洛兹美医疗 (HALO.US)首席执行官海伦·托利 (Helen Torley)称，公司计划以现金形式融资20亿欧元 (合21亿美元)收购德国Evotec公司 ...
第一黄金网2 天
美股前瞻 | 三大股指期货涨跌不一 特斯拉(TSLA.US)盘前大涨
盘前市场动向1. 11月18日(周一)美股盘前，美股三大股指期货涨跌不一。截至发稿，道指期货跌0.40%，标普500指数 盘前市场动向 1. 11月18日(周一)美股盘前，美股三大股指期货涨跌不一。截至发稿，道指期货跌0.40%，标普500指数期货涨0.02%，纳指期货涨0.37%。 2. 截至发稿，德国DAX指数跌0.34%，英国富时100指数涨0.13%，法国CAC40指数跌0.28%，欧洲斯 ...
奥洛兹美医疗拟以21亿美元现金收购Evotech
据报道，奥洛兹美医疗（HALO.US）首席执行官海伦·托利（Helen Torley）称，公司计划以现金形式融资20亿欧元（合21亿美元）收购德国Evotec公司（EVO.US）。Torley在接受采访时表示：“我们有信心以全额现金交易的方式为这笔交易提供资金。不会动用股权。她表示：“由于我们承担了一些债务，我们强劲的现金流将能够在交易完成后迅速将我们的杠杆率降至两倍。” ...
Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says
Halozyme Therapeutics Inc. plans to finance its €2 billion ($2.1 billion) proposed takeover of Germany’s Evotec SE in cash, ...
Halozyme plans finance $2.1 takeover of Evotech in cash: report
Halozyme Therapeutics (NYSE:HAL) intends to finance its 2B euro ($2.1B) proposed acquisition of Germany’s Evotec (EVO) in ...
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 ...
Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance ...
MT Newswires on MSN5 天
Halozyme Submits $2.11 Billion Acquisition Offer For Evotec
Halozyme Therapeutics (HALO) offered to acquire German drug maker Evotec (EVO) in a deal with an equity value of 2 billion euros ($2.11 billion). Halozyme submitted a non-binding proposal to Evotec's ...
Halozyme Therapeutics, Inc.: Halozyme Confirms Proposal to Combine with Evotec for €11.00 ...
Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team SAN ...
Evotec surges on Halozyme takeover interest
Evotec surged on Friday after Halozyme Therapeutics confirmed it had submitted a non-binding proposal to buy the German ...